MedTrace Logo

Clinical Evaluation of Florbetapir in Primary Progressive Aphasia

NCT04726527 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2024-10-16

No results posted yet for this study

Summary

The purpose of this research is to better understand how dementia affects activity in different parts of the brain.

Conditions

  • Primary Progressive Aphasia
  • Alzheimer Disease
  • Dementia

Interventions

DRUG

Florbetapir F 18

A single injection of 10 mCi (370 MBq) florbetapir F 18 will be administered by intravenous bolus injection.

DEVICE

Positron Emission Tomography

PET Scan for brain imaging

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Emily Rogalski, Ph.D · University of Chicago

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-15
Primary Completion
2015-09-02
Completion
2017-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04726527 on ClinicalTrials.gov